Metabolic Syndrome
Conditions
Brief summary
The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical study. Seventy-eight individuals will be screened, and considering a screening failure rate of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either BioPB-01 or Placebo
Interventions
OTHERBioPB-01
2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
OTHERPlacebo
2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
Sponsors
Vedic Lifesciences Pvt. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Stratified block randomization, Sequentially numbered, sealed, opaque envelopes
Intervention model description
randomized, double-blind, placebo-controlled, parallel-group
Eligibility
Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Participants who are 25 to 55 years of age (inclusive) at the time ofsigning the informed consent form. 2. Participants having good general health (no active or uncontrolled diseases, infections, or conditions). 3. BMI within the range of 24.9 to 34.9 kg/m2 (inclusive). 4. Random blood glucose level \<140 mg/dL. 5. Concurrent metformin use is acceptable for indications other than diabetes. (However, the subject and investigator must not change metformin dosing during the three weeks of the study). 6. Non-pregnant and non-lactating females of childbearing potential who agree to use adequate contraception/sexual abstinence throughout the study period. 7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures. 8. Individuals with access to a digital device to fill out the questionnaires.
Exclusion criteria
1. Participant has a history of uncontrolled hypertension (i.e., ≥150 mmHg systolic and/or ≥110 mmHg diastolic). 2. Participant with history of post-prandial hypoglycemia (occurring 2-5 hours after food intake) of unknown cause. 3. Abnormal thyroid-stimulating hormone (TSH) levels (\<0.4 or \> 4.2 μIU/ml). 4. Known case of Type 1 or 2 diabetes. 5. Participant has a history of heart disease and/or cardiovascular disease, kidney disease (dialysis or renal failure), and/or hepatic impairment or disease. 6. Participant has a history of previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the year prior to screening, immune disorder (i.e., HIV/AIDS), or a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit. 7. Received a vaccine for COVID-19 or any other vaccination in the 2 weeks prior to screening or planned during the study period, currentCOVID-19 infections, or currently have the post COVID-19 condition as defined by the World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis). 8. Have a known intolerance, sensitivity, or allergy to any of the study products, their ingredients, or any excipients used in the formulation. 9. Individuals who have a known history of diverticulitis. 10. Have a known intolerance, sensitivity, or allergy to milk or soy. 11. Any condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the study data. 12. Currently taking dietary supplements other than vitamins and minerals. 13. Taking any other prescription medication at the time of randomization that is known to impact blood sugar and or blood sugar metabolism, as per the Principal Investigator's (PI) discretion. 14. History of smoking, alcohol (heavy drinking as defined by NIAAA \[National Institute on Alcohol Abuse and Alcoholism\], USA), or substance abuse in the 12 months prior to screening. 15. Receipt or use of an investigational product in another research study within 30 days prior to baseline/Visit 2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety of 21 days of BioPB-01 administration on | Day 21 | The gastrointestinal (GI) health assessed using a modified Gastrointestinal Symptom Questionnaire (GSQ) compared to baseline and placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing the metabolic health | Day 21 | As assessed by the serum lipid profile (Triglycerides (TG), Total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) level from Baseline |
| To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing | Day 21 | The insulin sensitivity as assessed by HOMA-IR from baseline |
| To evaluate the efficacy of BioPB-01 after 21 days of administration by assessing Fecal short chain fatty acids (SCFA) | Day 21 | Namely acetate, propionate, and butyrate from Baseline. The samples will be analysed using liquid chromatography tandem mass spectrometry (LC-MS/MS). |
Countries
India
Outcome results
None listed